In their study of 591 bone marrow samples of de novo AML, 35.2% of patients showed cytoplasmic NPM1, while cytoplasmic NPM1 was not observed either in 135 secondary AMLs or in 980 neoplasms other than AML. This evidence concerns the gene NPM1 and neoplasm.